Guidance on the Use of Gemcitabine for the Treatment of Pancreatic Cancer (TA25)

Technology Appraisal Guidance No. 25

Source: National Institute for Health and Care Excellence

  • Gemcitabine may be considered as a treatment option for patients with advanced or metastatic adenocarcinoma of the pancreas and a Karnofsky performance score of 50 or more, where first line chemotherapy is to be used.

  • Gemcitabine is not recommended for patients who are suitable for potentially curative surgery, or patients with a Karnofsky (see Appendix D) score of less than 50.

  • There is insufficient evidence to support the use of gemcitabine as a second line treatment in patients with pancreatic adenocarcinoma.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at

Copies of the document can also be obtained by contacting 0845 003 7783 or emailing and quoting reference number 23811.

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:

Guidance on the Use of Gemcitabine for the Treatment of Pancreatic Cancer.
Issue Date: May 2001
Review Date: April 2004

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in